The manufacturer of the specific Abiraterone 250 mg product represented by this website is:
This should not be replaced with the name of the original developer or reference-product company unless product-specific documentation confirms the relationship.
Development history
Abiraterone originated from research into androgen synthesis inhibition at the Institute of Cancer Research. Its clinical development was subsequently associated with Cougar Biotechnology.
Reference medicine
Zytiga is the reference medicine containing abiraterone acetate. The EMA identifies Janssen-Cilag International N.V. as the marketing authorization holder for Zytiga in the EU.
Generic products
Other companies manufacture or hold authorization for generic abiraterone products. EMA records demonstrate that different generic products can have different marketing authorization holders while referencing Zytiga as the reference medicine.
Manufacturer versus developer
A medicine’s:
- Original developer
- Reference-product manufacturer
- Current manufacturer
- Brand owner
- Marketing authorization holder
- Distributor
may be different entities.
Quality information
Specific GMP certification, manufacturing site, batch-release arrangements or regulatory certifications for this website’s product are:
[Information requires verification]
Official information
Only official corporate and regulatory sources should be used to establish manufacturer identity.